Department of Otorhinolaryngology-Head and Neck Surgery, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, #7 Keunjaebong-gil, Hwaseong-si, 18450, Korea.
Sci Rep. 2024 Feb 9;14(1):3321. doi: 10.1038/s41598-024-53978-1.
The optimal treatment for sudden sensorineural hearing loss (SSNHL) is unclear. Hyperbaric oxygen therapy (HBOT) has been suggested as a viable option for treatment of SSNHL as it improves vascular dysfunction. In this study, we evaluated the therapeutic effects of HBOT by retrospectively reviewing the records of 2206 patients with SSNHL. 54 who had received HBOT were selected for the HBOT groups, while 59 age-matched controls who had not were selected for the control groups. The HBOT and control groups were divided into subgroups according to intratympanic steroid (ITS) use. Groups A-D had received oral steroids + HBOT, oral steroids only, oral steroids + ITS + HBOT, and oral steroids + ITS, respectively. Of the 113 SSNHL patients, 21 had diabetes mellitus (DM) (2, 0, 9, and 10 patients in Groups A-D, respectively). There was no notable difference in hearing improvement between patients receiving HBOT and those in the control group. However, among diabetic patients, those who underwent HBOT demonstrated a significant improvement in hearing when compared to the control group. The combination of HBOT and steroids could potentially be beneficial for treating severe to profound SSNHL patients with DM.
突发性聋（SSNHL）的最佳治疗方法尚不清楚。高压氧治疗（HBOT）因其可改善血管功能，已被提议作为治疗 SSNHL 的一种可行选择。在这项研究中，我们通过回顾性分析 2206 例 SSNHL 患者的记录来评估 HBOT 的治疗效果。选择了 54 名接受 HBOT 的患者作为 HBOT 组，同时选择了 59 名年龄匹配但未接受 HBOT 的患者作为对照组。根据鼓室内类固醇（ITS）的使用情况，HBOT 和对照组分为亚组。A-D 组分别接受口服类固醇+HBOT、口服类固醇、口服类固醇+ITS+HBOT 和口服类固醇+ITS。113 例 SSNHL 患者中有 21 例患有糖尿病（DM）（A-D 组分别为 2、0、9 和 10 例患者）。接受 HBOT 的患者与对照组患者在听力改善方面无显著差异。然而，在糖尿病患者中，与对照组相比，接受 HBOT 的患者听力有显著改善。HBOT 和类固醇的联合应用可能对治疗伴有糖尿病的重度至极重度 SSNHL 患者有益。
